SecBot SecBot
8-K ·Filed Jun 15, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago SEC0001628280-26-043232
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The primary catalyst is PALISADE-4 topline results expected within days. Positive results could drive a significant rally given the $23M market cap and prior PALISADE-2 success; negative results would likely lead to substantial downside given limited pipeline and cash runway. Monitor for the press release and consider positioning ahead of the binary event.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6900
T+0 close · Jun 15, 2026 · via day close
Latest settled
−65.36%
T+60 · $0.2390
Vs SPY
−66.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $0.6900entry
  2. T+1 · 5mo ago 0.00%α +1.25% · $0.6900
  3. T+5 · 5mo ago −8.36%α −6.13% · $0.6323
  4. T+20 · 4mo ago −64.33%α −64.53% · $0.2461
  5. T+60 · 2mo ago −65.36%α −66.36% · $0.2390
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen reported fiscal year 2026 financial results with net loss widening to $69.7M and cash at $45.4M, while providing pipeline updates including the imminent PALISADE-4 Phase 3 topline readout for fasedienol in social anxiety disorder. The filing is a routine pre-revenue biotech earnings update with no financial surprises; the stock will move on the binary PALISADE-4 results expected this month.

Key Facts

  • Total revenues for FY2026 were $1.269M (sublicense and other), up from $0.486M in FY2025.
  • Net loss was $69.685M for FY2026, compared to $51.418M in FY2025.
  • Cash, cash equivalents, and marketable securities were $45.4M as of March 31, 2026, sufficient to fund operations into 2027.
  • PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder: randomized portion completed, topline results expected in June 2026.
  • Phase 2 repeat dose study of fasedienol completed randomized portion, topline results expected in Q3 2026.
  • FDA issued 'Study May Proceed' letter for refisolone IND for vasomotor symptoms due to menopause.
  • Minimum ICH E1 safety exposure achieved with >1,500 individuals exposed to fasedienol.

Financial Impact

Net loss increased 35.5% YoY to $69.7M; cash burn rate approximately $24M/year. The upcoming PALISADE-4 readout is a binary catalyst that could swing market cap by >50%.

net losscash positionR&D expense

Risk Factors

  • PALISADE-4 may fail to meet its primary endpoint, similar to PALISADE-3, which would severely impair the pipeline.
  • Cash runway only into 2027; failure of PALISADE-4 could necessitate dilutive financing or restructuring.
  • No approved products or recurring revenue; stock is entirely dependent on clinical trial outcomes.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-043232
Document: vtgn-20260615.htm0001628280-26-043232
Document: 0001628280-26-043232-index-headers.html0001628280-26-043232
Document: 0001628280-26-043232-index.html0001628280-26-043232
Document: 0001628280-26-043232.txt0001628280-26-043232
8-K Data (Synthetic)0001628280-26-043232

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026